The most recent trading session ended with Johnson & Johnson (JNJ) standing at $154.42, reflecting a -0.63% shift from the previouse trading day's closing. The stock's change was less than the S&P ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Dr. Jared Weiss sat down for an interview to discuss a trial evaluating JNJ-1900, an immune-stimulating radiation sensitizer, in those with lung cancer. JNJ-1900, an immune-stimulating radiation ...

Johnson & Johnson recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced prostate cancer, which may have influenced its stock's 1.5% rise last week.

CHICAGO - Johnson & Johnson revealed initial results from a Phase 1 trial of its investigational trispecific antibody, JNJ-5322, for treating relapsed or refractory multiple myeloma, with a ...

Johnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, plus ...

Johnson & Johnson released promising Phase 3 results from the AMPLITUDE study evaluating niraparib combined with abiraterone acetate plus prednisone (AAP) in metastatic castration-sensitive ...

I maintain my buy rating on JNJ, citing attractive valuation, improved technicals, and a raised intrinsic value target of $184 per share. JNJ's recent earnings beat expectations, with strong ...

Johnson & Johnson said Wednesday that it is recalling five of its sunscreen products after some samples were found to contain low levels of benzene, a chemical that can cause cancer with repeated ...